Thomas Hedemann

Apr 30, 2024 | mondaq.com | Chad Landmon |Matthew Murphy |Thomas Hedemann

Two weeks ago we discussed Vanda Pharmaceuticals' ambitious cert petition asking the Supreme Court to discontinue the "reasonable expectation of success" standard for patent obviousness that for decades has been a mainstay of patent law. Vanda argued that the Court should instead adopt a "predictable results" standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries.

Apr 23, 2024 | jdsupra.com | Thomas Hedemann |Chad Landmon |Matthew Murphy

Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law. Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries.

Apr 17, 2024 | mondaq.com | Chad Landmon |Matthew Murphy |Thomas Hedemann

Among the most established standards in patent law is that obviousness requires a motivation to combine the prior art with "a reasonable expectation of success." The Federal Circuit alone has employed the "reasonable expectation" formulation in hundreds of opinions spanning the past four decades.

Apr 9, 2024 | jdsupra.com | Thomas Hedemann |Chad Landmon |Matthew Murphy

Among the most established standards in patent law is that obviousness requires a motivation to combine the prior art with “a reasonable expectation of success.” The Federal Circuit alone has employed the “reasonable expectation” formulation in hundreds of opinions spanning the past four decades.

Sep 11, 2023 | mondaq.com | Ted Mathias |Thomas Hedemann |Patrick Doyle

The Supreme Court heard arguments yesterday in Amgen v. Sanofi, the closely-watched case involving the enablement standard for patent claims, particularly as applied to functionally-defined genus claims.